Skip to main content

Table 5 Previous studies on preclinical antidiabetic potential of myricetin

From: Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

Compound / Plant species Model Results Ref.
Myricetin in vivo Enhanced enzymatic and non-enzymatic antioxidant defense system and showed protective effects against oxidative damage in liver and kidney of streptozotocin-cadmium-induced diabetic model. [109]
Myricetin in vivo Inhibitory activity against α-glucosidase (IC50 = 414 μM) in dose dependent manner. [110]
Myricetin in vivo Anti-hyperglycemic and renoprotective effects at 1.0 mg/kg. [111]
Myricetin in vivo Improved and re-established renal functions and activities of the glutathione peroxidase and xanthine oxidase enzymes in diabetic rat model. [112]
Myricetin in vivo Antidiabetic activity against t-BHP-induced oxidative stress. [113]
Myricetin in vivo Reduced glycemia in diabetic rats up to 50% after 2 days of treatment at 3 mg/12 h. [114]
Myricetin in vivo Stimulated lipogenesis in rat adipocytes and enhanced the stimulatory effect of insulin (EC50 = 65 μM). [115]
Myricetin in vitro Inhibited intestinal α-glucosidase (29%) and porcine α-amylase (64%) with IC50 vale of 0.38 mM. [116]
Abelmoschus moschatus Medik. (aerial part) in vivo Improved insulin sensitivity in rats. [117]
Ampelopsis grossedentata (Hand.-Mazz.) W.T. Wang (leaves) in vivo Inhibitory activity against α-glucosidase (IC50 = 319.3 μM). [118]
Azadirachta indica A.Juss. (leaves) in vivo Enhanced insulin signaling pathway and glucose utilization in skeletal muscle. [119]
Hovenia dulcis Thunb. (seeds) in vitro Inhibited intestinal α-glucosidase with IC50 = 3 μg/mL and α-amylase with IC50 = 662 μg/mL. [120]
Myrtus communis L. (leaves) in vivo Significant antidiabetic activity in diabetic models. [121]
Syzygium cumini (L.) Skeels (seeds) in vitro Inhibitory activity against α-glucosidase (IC50 = 1.7 μg/mL) and α-amylase (IC50 = 7.62 μg/mL). [122]
Syzygium malaccense (L.) Merr. & L.M.Perry (leaves) in vitro Inhibitory activity against α-glucosidase (IC50 = 15.52 μg/mL) and α-amylase (IC50 = 147.30 μg/mL). [123]